{"id":"W3129325639","doi":"10.1016/j.jaad.2021.02.028","title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"Eli Lilly and Company; Intel Corporation","keywords":"Medicine; Atopic dermatitis; Randomized controlled trial; Dermatology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000220405,0.0001694359,0.001273568,0.0002112755,0.00004812972,0.00001106196,0.0002526995,0.00007512849,0.000009943575],"category_scores_gemma":[0.0006309963,0.00009268451,0.00009801711,0.0004900992,0.000390468,0.00006878755,0.00003895323,0.0005385506,2.750134e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004691407,"about_ca_system_score_gemma":0.0004760846,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02138421,"about_ca_topic_score_gemma":0.00688807,"domain_scores_codex":[0.9969018,0.001339087,0.001025897,0.0001605717,0.0003397658,0.0002329479],"domain_scores_gemma":[0.9972066,0.00152364,0.000893,0.0001588832,0.0001078136,0.0001101067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7605804,0.0008717446,0.2225482,0.00003851758,0.000576727,0.0008447948,0.002106335,0.0004067344,0.00001716257,0.00003677775,0.01125303,0.0007196707],"study_design_scores_gemma":[0.7346116,0.0001987458,0.2592378,0.0002548879,0.0002406535,0.001274728,0.001251263,0.0005651521,0.0004688546,0.0006147971,0.001133733,0.0001477874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9580887,0.0003841028,0.00002489939,0.0408239,0.00005757207,0.0005114936,0.00007742422,0.000002734677,0.00002919814],"genre_scores_gemma":[0.9807227,0.0003226976,0.0002102034,0.01866552,0.00002351808,0.00001212241,0.00002606864,0.00001083844,0.000006290211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03668961,"threshold_uncertainty_score":0.9851325,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01039711786219512,"score_gpt":0.276569757015411,"score_spread":0.2661726391532159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}